Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 4/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30528606 | 0.95 | TSHR (0.56) | TSHRKDM4EHPGDHSD17B10L3MBTL1 | |
| SCHEMBL3568604 | 0.95 | TSHR (0.56) | TSHRKDM4EHPGDHSD17B10L3MBTL1 | |
| SCHEMBL2122821 | 0.87 | TSHR (0.58) | TSHRKDM4EHPGDHSD17B10L3MBTL1 | |
| SCHEMBL10831722 | 0.86 | TSHR (0.49) | TSHRKDM4EHPGDHSD17B10L3MBTL1 | |
| SCHEMBL7285841 | 0.83 | L3MBTL1 (0.46) | TSHRL3MBTL1ALDH1A1KCNH3TLR8 | |
| SCHEMBL7522536 | 0.83 | KDM4E (0.54) | TSHRKDM4EHPGDHSD17B10L3MBTL1 | |
| SCHEMBL3477013 | 0.81 | TSHR (0.51) | TSHRKDM4EHPGDHSD17B10L3MBTL1 | |
| SCHEMBL1724131 | 0.81 | L3MBTL1 (0.51) | TSHRKDM4EHPGDHSD17B10L3MBTL1 | |
| SCHEMBL10831309 | 0.81 | KDM4E (0.47) | TSHRKDM4EHPGDHSD17B10GAA | |
| SCHEMBL27520238 | 0.81 | TSHR (0.50) | TSHRKDM4EHPGDHSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1997007105-A1 | SUBSTITUTED QUINAZOLIN(THI)ONES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-02-27 | — | — | WO | claimed |
| EP-2033645-A1 | Isoquinoline derivatives and methods of use thereof | Inotek Pharmaceuticals Corporation (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-1603568-A4 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20080262016-A1 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| US-7393955-B2 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1784186-A4 | METHODS FOR TREATING OR PREVENTING ERECTILE DYSFUNCTION OR URINARY INCONTINENCE | INOTEK PHARMACEUTICALS CORP (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1722797-A4 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2008-03-19 | — | — | EP | disclosed |
| US-7268143-B2 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1784186-A2 | METHODS FOR TREATING OR PREVENTING ERECTILE DYSFUNCTION OR URINARY INCONTINENCE | Inotek Pharmaceuticals Corporation (US) | 2007-05-16 | — | — | EP | disclosed |
| EP-1722797-A1 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | Inotek Pharmaceuticals Corporation (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2006009718-A2 | METHODS FOR TREATING OR PREVENTING ERECTILE DYSFUNCTION OR URINARY INCONTINENCE | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20050282848-A1 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-12-22 | — | — | US | disclosed |
| EP-1603568-A2 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | Inotek Pharmaceuticals Corporation (US) | 2005-12-14 | — | — | EP | disclosed |
| US-6956035-B2 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-10-18 | — | — | US | disclosed |
| US-20050228007-A1 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2005-10-13 | — | — | US | disclosed |
| WO-2005082368-A1 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050049270-A1 | Isoquinoline derivatives and methods of use thereof | JAGTAP PRAKASH (US) | 2005-03-03 | — | — | US | disclosed |
| WO-2004078712-A2 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040039009-A1 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2004-02-26 | — | — | US | disclosed |
| WO-1997007105-A1 | SUBSTITUTED QUINAZOLIN(THI)ONES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228007-A1 | Isoquinoline derivatives and methods of use thereof | GLS, PINK1, PARK7 | TSHR 4771/4885KDM4E 3282/4885HPGD 128/4885 |
| US-20080262016-A1 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | CYP3A7, CYP3A5, ABCG2 | TSHR 4622/4885KDM4E 1995/4885HPGD 210/4885 |
| US-20050282848-A1 | Isoquinoline derivatives and methods of use thereof | CYP3A7, CYP3A5, ABCG2 | TSHR 4622/4885KDM4E 1995/4885HPGD 210/4885 |
| US-20040039009-A1 | Isoquinoline derivatives and methods of use thereof | CYP3A7, CYP3A5, ABCG2 | TSHR 4622/4885KDM4E 1995/4885HPGD 210/4885 |
| US-20050049270-A1 | Isoquinoline derivatives and methods of use thereof | CYP3A7, CYP3A5, ABCG2 | TSHR 4622/4885KDM4E 1995/4885HPGD 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.